Opinion
Video
Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.
Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma
Anito-Cel Yields 100% Response Rate in R/R Myeloma
Durcabtagene Autoleucel Yields High Response Rates in R/R Myeloma
Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma
2 Commerce Drive
Cranbury, NJ 08512